Philipp Koehler
YOU?
Author Swipe
View article: Molecular diagnostics in cancer patients with suspected respiratory mold infections
Molecular diagnostics in cancer patients with suspected respiratory mold infections Open
Invasive fungal infections (IFIs), including aspergillosis and mucormycosis, are serious complications in cancer patients. Reliable detection of etiologic agents is challenging but important for optimal patient management. In a prospective…
View article: Post‐ <scp>COVID</scp> Fatigue Is Associated With Reduced Cortical Thickness After Hospitalization
Post‐ <span>COVID</span> Fatigue Is Associated With Reduced Cortical Thickness After Hospitalization Open
Objective Neuropsychiatric symptoms are among the most prevalent sequelae of COVID‐19, particularly among hospitalized patients. Recent research has identified volumetric brain changes associated with COVID‐19. However, it currently remain…
View article: The 2025 EQUAL <i>Pneumocystis</i> Score—an ECMM tool to measure QUALity in <i>Pneumocystis</i> pneumonia management
The 2025 EQUAL <i>Pneumocystis</i> Score—an ECMM tool to measure QUALity in <i>Pneumocystis</i> pneumonia management Open
Background Pneumocystis pneumonia (PCP) is an opportunistic fungal infection. Several guidelines have been published to support its clinical management. However, the complexity and breadth of these guidelines pose challenges for consistent…
View article: Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults
Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults Open
Although the characteristics of complicated candidaemia are well known, uncomplicated disease remains undefined. Recommended treatment duration for candidaemia is 14 days after bloodstream infection is cleared. Longer treatment duration mi…
View article: Mortality of <i>Pneumocystis jirovecii</i> pneumonia in intensive care units: a post-hoc analysis of an international multicenter study by ESGCIP and EFISG
Mortality of <i>Pneumocystis jirovecii</i> pneumonia in intensive care units: a post-hoc analysis of an international multicenter study by ESGCIP and EFISG Open
PJP mortality remains high in ICU patients. Conditions other than HIV infection are emerging not only as non-classical risk factors for PJP development, but also as important mortality predictors. A better understanding of the reasons unde…
View article: P-1030. Mortality attributable to candidemia: Results from the European Confederation of Medical Mycology Multinational Observational Cohort Study Candida III
P-1030. Mortality attributable to candidemia: Results from the European Confederation of Medical Mycology Multinational Observational Cohort Study Candida III Open
Background Despite advances in antifungals, Candida infections still have a high mortality rate of up to 40%. The ECMM Candida III study in Europe investigated the changing epidemiology and outcomes, highlighting the need to understand and…
View article: Systematic assessment of COVID-19 host genetics using whole genome sequencing data
Systematic assessment of COVID-19 host genetics using whole genome sequencing data Open
Courses of SARS-CoV-2 infections are highly variable, ranging from asymptomatic to lethal COVID-19. Though research has shown that host genetic factors contribute to this variability, cohort-based joint analyses of variants from the entire…
View article: Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection
Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection Open
Introduction A clear immune correlate of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has not been defined. We explored antibody, B-cell, and T-cell responses to the third-dose vaccine and relation…
View article: Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B) Open
A second booster of either BNT162b2 or mRNA-1273 provided substantial IgG increase. Full-dose mRNA-1273 provided higher IgG levels and neutralizing capacity against SARS-CoV-2, with similar safety profile for subjects of advanced age.
View article: SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir Open
Background Although antivirals remain important for the treatment COVID-19, methods to assess treatment efficacy are lacking. Here, we investigated the impact of remdesivir on viral dynamics and their contribution to understanding antivira…
View article: Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM
Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM Open
Standardized research definitions were developed for proven invasive candidiasis, probable deep-seated candidiasis, proven invasive aspergillosis, probable invasive pulmonary aspergillosis, and probable tracheobronchial aspergillosis. The …
View article: The Cologne ECMM Excellence Center: A Two-Year Analysis of External Consultation Service for Invasive Fungal Infections
The Cologne ECMM Excellence Center: A Two-Year Analysis of External Consultation Service for Invasive Fungal Infections Open
The European Confederation of Medical Mycology (ECMM), formed due to the surge in invasive fungal infections (IFI), initiated the Excellence Centers program in 2016 to guide stakeholders to leading medical mycology sites. This report focus…
View article: 2383. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: a randomised trial in adults ≥75 years (EU-COVAT-1) from the VACCELERATE consortium
2383. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: a randomised trial in adults ≥75 years (EU-COVAT-1) from the VACCELERATE consortium Open
Background Vaccination remains crucial for protection against severe SARS-CoV-2 infection, especially in aged population. Methods We evaluated, with a randomised controlled, adaptive, multicentre phase II study, the safety and immunogenici…
View article: Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time
Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time Open
SARS-CoV-2 neutralising antibodies provide protection against COVID-19. Evidence from early vaccine trials suggested binding antibody thresholds could serve as surrogate markers of neutralising capacity, but whether these thresholds predic…
View article: Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)
Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1) Open
This trial was funded by the European Commission (Framework Program HORIZON 2020).
View article: Questioning the 14‐day dogma in candidemia treatment duration
Questioning the 14‐day dogma in candidemia treatment duration Open
The growing threat of antimicrobial resistance (AMR) is a global concern. With AMR directly causing 1.27 million deaths in 2019 and projections of up to 10 million annual deaths by 2050, optimising infectious disease treatments is imperati…
View article: Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia
Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia Open
Objectives Fosmanogepix (APX001), a first-in-class, intravenous (IV) and oral (PO) antifungal prodrug, is being developed to treat invasive fungal diseases (IFDs). Manogepix (APX001A; active moiety) targets fungal glycosylphosphatidylinosi…
View article: Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry Open
Hospitalisation and mortality rates with molnupiravir were comparable to those with nirmatrelvir/ritonavir in high-risk patients with haematological malignancies and COVID-19. Molnupiravir is a plausible alternative to nirmatrelvir/ritonav…
View article: Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study
Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study Open
Background To date, azoles represent the only viable option for oral treatment of invasive Candida infections, while rates of azole resistance among non-albicans Candida spp. continue to increase. The objective of this sub-analysis of the …